The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will fulfil the 2013 ACR/EULAR SSc criteria within 5 years.
All News
Article
Article
New work presented at the 2025 annual EULAR congress in Barcelona focuses on the recombinant zoster vaccine (RZV), which contains recombinant glycoprotein E – the major target of CD4+T-cells.
Article
Social Determinants of Health in SLE
EurekAlert!
Social determinants of health (SDH), such as socioeconomic status and educational background are factors that are increasingly recognised as critical contributors to health outcomes in chronic diseases.
Article
Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists. Here are a few interesting presentations from today.
🌍Patients w RMDs across 🇫🇷🇳🇱🇨🇭🇹🇷 face different barriers to physical activity:
💶Cost =barrier in 🇳🇱
⛈️Weather =barrier in 🇹🇷
🧑⚕️HCP support =key in 🇫🇷
🏃Active transport & knowledge =enablers in 🇨🇭
Tailored physical activity interventions needed.
@RheumNow #EULAR2025 #OP0382-HPR https://t.co/lk7fwDHDe7
David Liew
Tweet
Very pleased to present at #EULAR2025 work @ArthritisAust on consumer involvement into research.
Consumer involvement in research delivers:
- better, more relevant research
- better dissemination of results
- competitiveness in today’s funding landscape
POS1016-PARE @RheumNow https://t.co/0fhpsnGhdT
Adela Castro
Tweet
High dose NSAIDs and incidence of HTN in axSpA?
In pts with early axSpA(age at baseline 33.2 years) data from DESIR cohort showed that after adjusting for confounders,high dose NSAID use was not associated with incident hypertension (HR 1.01, 95% CI 0.98-1.02).
Interesting to
Adela Castro
Tweet
What is new in SpA?
‼️nomenclature change:
🚫AS≠ Ankylosing spondylitis
✅AS= Axial spondyloarthritis
-Helena Marzo-Ortega at #EULAR2025
@RheumNow
About #Multidisciplinarity ...
Dr Ihsane Hmamouchi talking about Multidisciplinary Approach to Migrant #Rheumatology Care
#quotes
#EULAR2025
#Invitedspeaker
#outofthebox
@RheumNow
@epirheum https://t.co/RG6xpHejv9
Diagnostic delay in #SpA
🔹️Data from the @Official_ASAS
Study
🔹️4339 patients
🔹️Delay was 6.6 years
🔹️Longer in axSpA and IBD-SpA, shorter in PsA and pSpA
🔹️Associated with type of initial symptoms (shorter in peripheral)
POS0909 #EULAR2025
@rheumnow https://t.co/3BMYFxbKiq
Janet Pope
Tweet
#neuromodulation in #rheumatoid #arthritis
What is it?
👇
Autonomic & immune system interaction
Who seeks this Rx?
desperate pts w pain
No Rx left
Interested in technology
#EULAR2025 @RheumNow @eular_org
#D2T #RA https://t.co/XWWFiUK6Em
Aurelie Najm
Tweet
The great debate: are cannabis and cannabinoids a valid treatment option in patients with rheumatic diseases?
A thread 🧵👇🏼
@RheumNow #EULAR2025 https://t.co/KLZN9MvcFy
David Liew
Tweet
So we used to get taught about bimodal age distribution of RA onset - young people and old people.
Actually, it’s early middle age where RA diagnoses have now grown globally over 30y - right in peak productivity
Global Burden of Disease data
#EULAR2025 OP0240-HPR @RheumNow https://t.co/8yyrex00yy
GRAPPA defines :
- D2T-PsA (failed ≥3 therapies incl. ≥2 b/tsDMARDs)
- CM(complex to manage)-PsA (adds pain, comorbidity, complexity).
A needed framework to improve trial design & real-world care.
Do these definitions fit your clinic?
#OP0175 @RheumNow #EULAR2025 https://t.co/ot1bVLIYLA
Bella Mehta
Tweet
Rheumatology #AI to optimize rheumatology triage. Only 53 percent correlation between the AIs diagnosis with rheumatologists final diagnosis. Not sure if we want 47 percent pts to drop off...without a chance for diagnosis?
#POS0883 #EULAR2025 @RheumNow https://t.co/UWsCHG00t1
OP0176: Among D2T PsA pts, 43% lacked inflammation on imaging—despite symptoms.
Clinical + US split them into PIPsA vs NIPsA, helping distinguish who needs escalation vs who doesn’t.
A step toward smarter care in D2T PsA.
@RheumNow #EULAR2025 https://t.co/E9igwvDPPN


